Clinical trial
Phase II Trial Evaluating the Immunogenicity and Safety of BBIBP-CorV Vaccine in Adults in Guinea
NCT05409300 is registered in ClinicalTrials.gov with ANRS, Emerging Infectious Diseases as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Trial Evaluating the Immunogenicity and Safety of BBIBP-CorV Vaccine in Adults in Guinea
- Lead sponsor
- ANRS, Emerging Infectious Diseases
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- April 25, 2022
- Completion date
- February 28, 2025
- Enrollment
- 200 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
covid-19, healthy volunteer, sars-cov-2 infection, vaccine adverse reaction